Showing posts with label DoJ HSR Comments Second Request Bayer Behringer Merial Intervet Pfizer Wyeth Animal Health FTC Hart Scott Divestitures Overlap Sanofi ECC Antitrust Reverse Merger August 21 2009. Show all posts
Showing posts with label DoJ HSR Comments Second Request Bayer Behringer Merial Intervet Pfizer Wyeth Animal Health FTC Hart Scott Divestitures Overlap Sanofi ECC Antitrust Reverse Merger August 21 2009. Show all posts

Friday, August 21, 2009

Italy's Dog/Cat Ear Infection Anti-Microbials Market: Highly-Concentrated


More, shortly (other duties call -- but I wanted to get this cute puppy graphic right out!); this is the third in the series -- Schering-Plough / Intervet / Merial-Sanofi/ "New Merck" would have 55 percent to 60 percent of the companion animal ear infection antimicrobials market in Italy -- and face only one serious competitor -- Janssen.

This is one more thing to write about, when you get ready to write the European Competition Commission.

You only have six days left to respond -- now that Sanofi-Aventis is acquiring the second half of Merck's Merial animal health venture, and is also being granted the right to buy all of Intervet, post the Schering-Merck merger. [Here are the earlier parts one, and parts two.]

Back in the Fall of 2007, as a part of Schering-Plough's original acquisition of Organon (and Intervet), the ECC required divestitures of a slew of animal health product lines. While it is exceedingly difficult to track which concerns bought which product lines, post 2007 (out of the Organon/Intervet acquisition required divestitures), what is clear is that if Merial and Intervet are combined, even in a 50-50 joint venture between Sanofi-Aventis and "New Merck" -- there will be significant, and increased, concentration in many animal health markets in Europe.

[Recall again that Sanofi-Aventis is buying Merial, from Merck, and then receiving a "call" option -- to buy all of Intervet, post the Schering-Plough/Merck merger.] With me so far? Good.:

. . . .The parties have a combined market share of [55-60]% (Schering-Plough: [10-20]%; Intervet: [10-20]%; Merial: [20-30]%), in Italy. The new entity would face only two competitors, only one of which has solid market share: Janssen: [30-40]. . . .

So, this is yet a[nother] public service mailer -- print, or cut and paste the above, and mail in the next ten days -- if you are at all concerned about preserving European price- and product-offering competition in animal health businesses. Mail it (Old School-style) to this address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
1049 Bruxelles/Brussel
BELGIQUE/BELGIËEN


"Whiskey for my men; beer for my horses. . . ."